Advancements in cancer chemotherapy
-
Krzysztof Koper
Abstract
Chemotherapy is in most cases a method of systemic treatment of malignant tumors with cytostatic drugs. Although modern methods such as immunotherapy or targeted therapy are used more and more often nowadays, the role of chemotherapy in oncology is still significant. It can be used as an independent treatment method or in combination with other oncological therapies. The action of chemotherapy is closely linked to the cell cycle of the tumor. Advances in technology allow the introduction of different pharmaceutical forms of the same drug. Worse prognosis of metastatic tumors justifies the need to search for new, more effective treatment methods. The main problem of chemotherapy is the occurrence of adverse events. Reducing the frequency and severity of side effects is possible primarily by changing the technique of implementation of chemotherapy administration. These principles are fulfilled by new, increasingly popular therapeutic methods, such as: Perioperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) or transarterial chemoembolization (TACE). The dynamic development of knowledge concerning cytostatic drugs, including targeting the tumor cell with the form of the drug, allows us to assume that in the future this direction will increase the effectiveness and safety of anticancer therapy.
-
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
-
Research funding: None declared.
-
Conflict of interest statement: The authors declare no conflicts of interest regarding this article.
References
1. Krzakowski, M, Wyrwicz, L. Leczenie systemowe. In: Krzakowski, M, Potemski, P, Warzocha, K, Wysocki, P, editors. Onkologia kliniczna, 3rd ed. Warsaw, Poland: Via Medica; 2014:107–34 pp.Search in Google Scholar
2. The classification of cytostatic drugs based on the anatomical therapeutic chemical classification system; 2020. Available from: https://www.whocc.no/atc_ddd_index/?code=L&showdescription=no.Search in Google Scholar
3. Orzechowska-Juzwenko, K. Leki przeciwnowotworowe. In: Kostowski, W, Herman, Z, editors. Podstawy Farmakologii, 2nd ed. Warsaw, Poland: PZWL; 2001:400–44 pp.Search in Google Scholar
4. DeVita, VT, Chu, E. Medical oncology. In: DeVita, VT, Lewrance, TS, Rosenber, SA, editors. Cancer-principales and practice oncology, 9th ed. Philadelphia, USA: Lippincott Wiliams & Wilkins; 2011:312–21 pp.Search in Google Scholar
5. Krämer, I, Heuser, A. Paclitaxel – pharmaceutical and pharmacological issues. Environ Health Perspect USA 1995;1:37–41.Search in Google Scholar
6. Müller, RH, Mäder, K, Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–77. https://doi.org/10.1016/S0939-6411(00)00087-4.Search in Google Scholar
7. Meng, Z, Lv, Q, Lu, J, Yao, H, Lv, X, Jiang, F, et al.. Prodrug strategies for paclitaxel. Int J Mol Sci 2016;17:796. https://doi.org/10.3390/ijms17050796.Search in Google Scholar PubMed PubMed Central
8. Miele, E, Spinelli, GP, Miele, E, Tomao, F, Tomao, S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed 2009;4:99–105. https://doi.org/10.2147/ijn.s3061.Search in Google Scholar PubMed PubMed Central
9. He, Z, Wan, X, Schulz, A, Bludau, H, Dobrovolskaia, MA, Stern, ST, et al.. A high capacity polymeric micelle of paclitaxel: implication of high dose drug therapy to safety and in vivo anti-cancer activity. Biomaterials 2016;101:296–309. https://doi.org/10.1016/j.biomaterials.2016.06.002.Search in Google Scholar PubMed PubMed Central
10. Rowinsky, EK, Donehower, RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004–14. https://doi.org/10.1056/nejm199504133321507.Search in Google Scholar
11. Chu, Z, Chen, JS, Liau, CT, Wang, HM, Lin, YC, Yang, MH, et al.. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anti Canc Drugs 2008;19:275–81. https://doi.org/10.1097/cad.0b013e3282f3fd2e.Search in Google Scholar PubMed PubMed Central
12. Huang, JR, Lee, MH, Li, WS, Wu, HC. Liposomal irinotecan for treatment of colorectal cancer in a preclinical model. Cancers 2019;11:281. https://doi.org/10.3390/cancers11030281.Search in Google Scholar PubMed PubMed Central
13. Abraham, SA, Waterhouse, DN, Mayer, LD, Cullis, PR, Madden, TD, Bally, MB. The liposomal formulation of doxorubicin. Methods Enzymol 2005;391:71–97. https://doi.org/10.1016/s0076-6879(05)91004-5.Search in Google Scholar PubMed
14. Batist, G, Barton, J, Chaikin, P, Swenson, C, Welles, L. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expet Opin Pharmacother 2002;3:1739–51. https://doi.org/10.1517/14656566.3.12.1739.Search in Google Scholar PubMed
15. Swenson, CE, Perkins, WR, Roberts, P, Janoff, AS. Liposome technology and the development of Myocet (liposomal doxorubicin citrate). Breast 2001;10:1–7. https://doi.org/10.1016/s0960-9776(01)80001-1.Search in Google Scholar
16. Niu, G, Cogburn, B, Hughes, J. Preparation and characterization of doxorubicin liposomes. Methods Mol Biol 2010;624:211–9. https://doi.org/10.1007/978-1-60761-609-2_14.Search in Google Scholar PubMed
17. Chang, HI, Yeh, MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed 2012;7:49–60. https://doi.org/10.2147/IJN.S26766.Search in Google Scholar PubMed PubMed Central
18. Balis, FM, Mirro, JJr, Reaman, GH, Evans, WE, McCully, C, Doherty, KM, et al.. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1998;6:1882–6. https://doi.org/10.1200/JCO.1988.6.12.1882.Search in Google Scholar PubMed
19. Anderson, KC, Landgren, O, Arend, RC, Chou, J, Jacobs, IA. Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Future Oncol 2019;15:3267–81. https://doi.org/10.2217/fon-2019-0368.Search in Google Scholar PubMed
20. Bittner, B, Richter, W, Schmidt, J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs 2018;32:425–40. https://doi.org/10.1007/s40259-018-0295-0.Search in Google Scholar PubMed PubMed Central
21. Probst, U, Fuhrmann, I, Beyer, L, Wiggermann, P. Electrochemotherapy as a new modality in interventional oncology: a review. Technol Canc Res Treat 2018;17:1–12. https://doi.org/10.1177/1533033818785329.Search in Google Scholar PubMed PubMed Central
22. Campana, LG, Marconato, R, Valpione, S, Galuppo, S, Alaibac, M, Rossi, CR, et al.. Basal cell carcinoma: 10-year experience with electrochemotherapy. J Transl Med 2017;15:122. https://doi.org/10.1186/s12967-017-1225-5.Search in Google Scholar PubMed PubMed Central
23. Kleinberg, L. Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy. Patient Prefer Adherence 2016;10:2397–406. https://doi.org/10.2147/PPA.S93020.Search in Google Scholar PubMed PubMed Central
24. Zhang, J, Kale, V, Chen, M. Gene-directed enzyme prodrug therapy. AAPS J 2015;17:102–10. https://doi.org/10.1208/s12248-014-9675-7.Search in Google Scholar PubMed PubMed Central
© 2021 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Reviews
- Non-collinear magnetism & multiferroicity: the perovskite case
- Fluorescent styryl chromophores with rigid (pyrazole) donor and rigid (benzothiophenedioxide) acceptor – complete density functional theory (DFT), TDDFT and nonlinear optical study
- Investigating the biological actions of some Schiff bases using density functional theory study
- Traditional uses, biological activities, and phytochemicals of Lecaniodiscus cupanioides: a review
- Protein modeling
- Advancements in cancer chemotherapy
- Synthesis of magnetic ferrogels: a tool-box approach for finely tuned magnetic- and temperature-dependent properties
Articles in the same Issue
- Frontmatter
- Reviews
- Non-collinear magnetism & multiferroicity: the perovskite case
- Fluorescent styryl chromophores with rigid (pyrazole) donor and rigid (benzothiophenedioxide) acceptor – complete density functional theory (DFT), TDDFT and nonlinear optical study
- Investigating the biological actions of some Schiff bases using density functional theory study
- Traditional uses, biological activities, and phytochemicals of Lecaniodiscus cupanioides: a review
- Protein modeling
- Advancements in cancer chemotherapy
- Synthesis of magnetic ferrogels: a tool-box approach for finely tuned magnetic- and temperature-dependent properties
